Led · Series A · Feb 2020

PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, develops a theranostic radiopharmaceutical pair targeting the CXCR4 receptor. Its lead compounds are PentixaFor, a [68Ga]-based PET imaging agent, and PentixaTher, a therapeutic labeled with α- or β-emitters for endoradiotherapy. PentixaFor has demonstrated advanced imaging across hematologic indications including leukemia, lymphoma and multiple myeloma, and in solid tumors such as adrenocortical carcinoma and small cell lung cancer; it can also visualize conditions like atherosclerosis, myocardial infarction, splenosis and stroke. The company plans clinical advancement with a phase II trial for PentixaFor and a phase I trial of PentixaTher in CNS lymphoma, while supporting proof-of-concept studies in additional indications. Funding from the Series A is dedicated to these clinical programs and to further establishing the CXCR4 theranostic approach. PentixaPharm positions itself to enable individualized radiopharmaceutical therapies for fast-progressing diseases, particularly malignant cancers.

Led · Equity · Mar 2014

Glycotope specializes in glycosylation of proteins and develops glycooptimized, fully human antibodies and protein therapeutics using its GlycoExpress (GEX) production technology. Its pipeline includes FSH-GEX (an improved fertility hormone), PankoMab-GEX and CetuGEX (both cancer antibodies), and TrasGEX, with PankoMab-GEX and CetuGEX in Phase IIb and TrasGEX having completed Phase I/IIa. The company plans to complete Phase IIb trials with several hundred patients in Europe and the U.S. before the end of 2016 and to start Phase III trials for FSH-GEX in summer 2014, each study involving roughly 1,000 patients per region. Management states the technology increases tolerability, effectiveness, and affordability of protein medicines. Glycotope was founded in 2001 at the Max-Delbrück-Center for Molecular Medicine and employs more than 180 people across Berlin and Heidelberg. The recent financing strengthens its ability to fund late-stage clinical development across multiple indications.

Participated · Equity · Apr 2011

OctreoPharm Sciences GmbH is a Berlin-based biopharmaceutical company focused on developing novel radiopharmaceuticals for neuroendocrine tumours. Its lead product is the diagnostic radiopharmaceutical SOMscan(R), intended for detection and treatment control of neuroendocrine tumours. The company closed a €5m financing round to fund the clinical development of SOMscan(R). Clinical trials up to Phase II are expected to be implemented within the next two years. If these trials succeed, OctreoPharm expects to seek European approval in 2014 following an additional financing round, with U.S. approval to follow thereafter. The company is led by founders Dr. Hakim Bouterfa (Managing Director, responsible for clinical development) and Udo Blaseg (Managing Director).